BRIVANIB (B) IN ADVANCED OVARIAN CANCER (OC): SUBSET RESULTS OF A PHASE 2 RANDOMIZED DISCONTINUATION TRIAL (RDT)

被引：0

作者：

Kaye, S. B. ^{[1
,2
]}

Siu, L. L. ^{[3
]}

Jassem, J. ^{[4
]}

Medioni, J. ^{[5
]}

Soetekouw, P. M. M. B. ^{[6
]}

Slater, S. ^{[7
]}

Rudin, C. M. ^{[8
]}

Schwartz, G. K. ^{[9
]}

De Jonge, M. ^{[10
]}

O'Dwyer, P. ^{[11
]}

Baudelet, C. ^{[12
]}

Chen, A. ^{[13
]}

Ratain, M. J. ^{[14
]}

机构：

[1] Royal Marsden Hosp, Sutton, Surrey, England

[2] Inst Canc Res, Sutton, Surrey, England

[3] Princess Margaret Hosp, Dept Med Oncol, Toronto, ON M4X 1K9, Canada

[4] Med Univ Gdansk, Gdansk, Poland

[5] Hop Europeen Georges Pompidou, Dept Med Oncol, Paris, France

[6] Maastricht Univ, Med Ctr, Div Med Oncol, Maastricht, Netherlands

[7] Beatson W Scotland Canc Ctr, Dept Med Oncol, Glasgow, Lanark, Scotland

[8] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[9] Mem Sloan Kettering Canc Ctr, Melanoma & Sarcoma Serv, New York, NY 10021 USA

[10] Erasmus Univ, Med Ctr, Dept Med Oncol, Rotterdam, Netherlands

[11] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[12] Brstol Myers Squibb, Res & Dev, Braine Lalleud, Belgium

[13] Bristol Myers Squibb Co, Res & Dev, Wallingford, CT 06492 USA

[14] Univ Chicago, Dept Med, Chicago, IL 60637 USA

来源：

ANNALS OF ONCOLOGY | 2012年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：319 / 319

页数：1

共 50 条

[21] Randomized phase II trial of NGR-hTNF with an anthracycline in platinum-refractory or -resistant ovarian cancer (OC).
Lorusso, Domenica
Scambia, Giovanni
Colombo, Nicoletta
Reed, Nicholas
Pisano, Carmen
Lord, Rosemary
Mangili, Giorgia
Mosconi, Annamaria
Raspagliesi, Francesco
Palazzo, Antonella
Ditto, Antonino
Salutari, Vanda
Conte, Carmine
Amadio, Giulia
Lambiase, Antonio
Bordignon, Claudio
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[22] Randomized Phase III Clinical Trial Evaluating Weekly Cisplatin for Advanced Epithelial Ovarian Cancer
Fruscio, Robert
Garbi, Annalisa
Parma, Gabriella
Lissoni, Andrea Alberto
Garavaglia, Daniela
Bonazzi, Cristina Maria
Dell'Anna, Tiziana
Mangioni, Costantino
Milani, Rodolfo
Colombo, Nicoletta
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (04) : 347 - 351
[23] Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
Cheng, Ann-Lii
Kang, Yoon-Koo
Lin, Deng-Yn
Park, Joong-Won
Kudo, Masatoshi
Qin, Shukui
Chung, Hyun-Cheol
Song, Xiangqun
Xu, Jianming
Poggi, Guido
Omata, Masao
Lowenthal, Susan Pitman
Lanzalone, Silvana
Yang, Liqiang
Lechuga, Maria Jose
Raymond, Eric
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (32) : 4067 - +
[24] A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma
Vergote, Ignace B.
Smith, David C.
Berger, Raanan
Kurzrock, Razelle
Vogelzang, Nicholas J.
Sella, Avishay
Wheler, Jennifer
Lee, Yihua
Foster, Paul G.
Weitzman, Ron
Buckanovich, Ronald J.
EUROPEAN JOURNAL OF CANCER, 2017, 83 : 229 - 236
[25] RESULTS FROM A PHASE I/II TRIAL OF TINOSTAMUSTINE MONOTHERAPY IN ADVANCED SOLID TUMOURS (NCT03345485): SAFETY AND EFFICACY IN A SUBSET OF PATIENTS WITH ADVANCED OVARIAN CANCER (OVCA)
Tinker, Anna V.
Chugh, Rashmi
Curigliano, Giuseppe
Kummar, Shivaani
Schneider, Reva
Strauss, James
Janik, Tomas
Manamley, Nick
Hilgier, Kasia
Oaknin, Ana
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 : A252 - A252
[26] Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trial
How, Jeffrey A.
Dang, Minghao
Lee, Sanghoon
Fellman, Bryan
Westin, Shannon N.
Sood, Anil K.
Fleming, Nicole D.
Shafer, Aaron
Yuan, Ying
Liu, Jinsong
Zhao, Li
Celestino, Joseph
Hajek, Richard
Morgan, Margaret B.
Parra, Edwin R.
Fernandez, Caddie D. Laberiano
Arrechedera, Claudio A.
Soto, Luisa Maren Solis
Schmeler, Kathleen M.
Nick, Alpa
Lu, Karen H.
Coleman, Robert
Wang, Linghua
Jazaeri, Amir A.
MED, 2025, 6 (01):
[27] Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial
Wu, Xiaohua
Liu, Jihong
Wang, Jing
Wang, Li
Lin, Zhongqiu
Wang, Xiaobin
Zhu, Jianqing
Kong, Beihua
Fei, Junwei
Tang, Ying
Xia, Bairong
Liang, Zhiqing
Wang, Ke
Huang, Yi
Zheng, Hong
Lin, An
Jiang, Kui
Wang, Wei
Wang, Xin
Lou, Ge
Pan, Hongming
Yao, Shuzhong
Li, Guiling
Hao, Min
Cai, Yunlang
Chen, Xuejun
Yang, Zhijun
Chen, Youguo
Wen, Hongwu
Qu, Pengpeng
Xu, Cong
Hsieh, Chih-Yi
NATURE MEDICINE, 2024, : 1612 - 1621
[28] Flames: randomized phase 3 trial of maintenance senaparib in patients with newly diagnosed advanced ovarian cancer
Wu, Xiaohua
Liu, Jihong
Wang, Xiaobin
Wang, Jing
Wang, Li
Zhu, Jianqing
Kong, Beihua
Fei, Junwei
Tang, Ying
Xia, Bairong
Liang, Zhiqing
Wang, Ke
Lin, Zhongqiu
Huang, Yi
Zheng, Hong
Lin, An
Jiang, Kui
Wang, Wei
Wang, Xin
Lou, Ge
Pan, Hongming
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (SUPPL_4) : A10 - A11
[29] Metformin for patients with advanced stage ovarian cancer: A randomized phase II placebo-controlled trial
Romero, Iris L.
Lengyel, Ernst
Hendrickson, Andrea E. Wahner
Rodriguez, Gustavo C.
Leath, Charles A.
Rocconi, Rodney P.
Goodheart, Michael J.
Dewdne, Summer
Karrison, Theodore
Fleming, Gini F.
Yamada, Diane
GYNECOLOGIC ONCOLOGY, 2025, 194 : 18 - 24
[30] Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT)
Ratain, MJ
Flaherty, KT
Stadler, WM
O'Dwyer, P
Kaye, S
Xiong, H
Patnaik, A
Gore, M
Lee, RJ
Eisen, T
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 382S - 382S

← 1 2 3 4 5 →